Vuxen Group (VUXEN) Q4 25/26 earnings summary

Executive summary

• Achieved record results for 2025/26, with revenue up 14.3% year-over-year to 245.7 MSEK and EBITDA up 91% to 23.1 MSEK, the highest in company history.

• Strategic focus on the core sexual health segment drove both growth and profitability, with improved marketing ROI and increased share of own brands.

• Strong Q4 performance: sales up 23.1% to 55.8 MSEK, EBITDA margin rose to 10.9% from 3.3% year-over-year.

• Board proposes a total dividend of 1.00 SEK per share, reflecting strengthened cash flow and profitability.

Financial highlights

• Q4 net sales: 55.8 MSEK (up 23.1% year-over-year); full year: 245.7 MSEK (up 14.3%).

• Q4 EBITDA: 6.1 MSEK (up 304%); full year EBITDA: 23.1 MSEK (up 91.1%).

• Q4 gross margin: 60.1% (up from 56.5%); full year gross margin: 60.5% (up from 58.2%).

• Cash flow from operations for the year: 19.4 MSEK (up from 1.4 MSEK).

• Cash and equivalents at year-end: 37.3 MSEK (up from 17.9 MSEK).

Outlook and guidance

• Entering 2026/27 with strong momentum and a robust balance sheet; continued focus on sexual health as the core business.

• Ongoing expansion in Germany and other European markets, leveraging scalable logistics and strong cash flow.

• Market growth and increased category acceptance expected to benefit all players, with the company well-positioned to gain further market share.